anti-retroviral

Hck-IN-1 is a selective Nef-dependent Hck inhibitor (IC50s: 2.8 μM and >20 μM for Nef:Hck complex and Hck) with antiretroviral activity. Hck-IN-1 is a direct and wide HIV-1 Nef antagonist with an IC50 of 100-300 nM for wild-type HIV-1 replication.

Stavudine (BMY-27857), a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV.

Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor analog of adenosine (IC50: 0.49 μM).

Cabotegravir (S/GSK1265744) (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM).

Lenacapavir (GS-6207) is the first HIV-1 capsid inhibitor approved by the U.S. Food and Drug Administration, the European Medicines Agency, and Health Canada for the treatment of MDR HIV-1 infection.[3]

Dexelvucitabine (RVT), a nucleoside reverse transcriptase inhibitor, is used potentially for the treatment of HIV infection.

AG 555 (Tyrphostin B46) is an EGFR tyrosine kinase inhibitor.

Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) is a rat-derived agonistic antibody targeting mouse 4-1BB/CD137 that can stimulate 4-1BB signaling and induce T cell-mediated anti-tumor immunity. Anti-Mouse 4-1BB/CD137 Antibody (LOB12.3) can be used in research on cancer, infection, immunology, and neurological diseases, such as glioblastoma and retroviral infection .